Blood and tumor samples for Genetic Profiling research

Biopsy

Antoine Italiano, MD PhD

Maxime Frelaut, MD

Maxime Frelaut, PhD

The objective of STING study is to perform high throughput molecular analysis (next generation sequencing +/- immunological profiling) to estimate the proportion of patients with cancer presenting at least one targetable genomic alteration.

STING is a biology driven, multicenter study designed to identify actionable molecular alterations in cancer patients and to explore mechanisms of sensitivity and resistance to anti-cancer treatment

* In this trial, high throughput analysis will be carried out using next generation sequencing, and immunological profiling
* Patients included in the STING study and for whom a targetable genomic alteration had been identified might be subsequently included in a clinical trial running at Gustave Roussy or another participating center.

The proportion of patients presenting at least one genomic alteration will be estimated in the eligible NGS population and reported using frequency and proportion. The 95% two-sided confidence limits (95%CI) will be provided for the estimated proportion (binomial law). In addition, counts, proportions and 95%CI will be reported for each individual genomic alteration.

Survival data will be analysed by standard time-to-event survival techniques.

Gustave Roussy Cancer Profiling

Number of patients presenting at least one targetable genomic alteration

Proportion of patients presenting at least one targetable genomic alteration

For a patient with molecular results available utilization of molecular profiling information is defined as Inclusion in a clinical trial assessing a drug matched to the molecular alteration And/or Treatment with an approved drug matched with the molecular alteration

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Gustave Roussy Cancer Profiling	NCT04932525	Solid Tumor, Un...	Biopsy	18 Years -	Gustave Roussy, Cancer Campus, Grand Paris
Gustave Roussy Cancer Profiling	NCT04932525	Solid Tumor, Un...	Biopsy	18 Years -	Gustave Roussy, Cancer Campus, Grand Paris
Gustave Roussy Cancer Profiling	NCT04932525	Solid Tumor, Un...	Biopsy	18 Years -	Gustave Roussy, Cancer Campus, Grand Paris

Spots Global Cancer Trial Database for targetable oncogenic aberration